Basic Information
Incellipan
Regulatory Information
EMEA/H/C/006051
April 19, 2024
February 22, 2024
May 2, 2024
Company Information
the netherlands
Paasheuvelweg 28 1105 BJ Amsterdam
Seqirus Netherlands B.V.
Drug Classification
Active Substances Detail
Influenza virus A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 strain, HA surface antigen
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Incellipan is indicated for active immunisation against influenza in an officially declared pandemic. Incellipan should be used in accordance with official recommendations.
Overview Summary
Incellipan is a [pandemic preparedness vaccine](https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/pandemic-influenza/vaccines-pandemic-influenza) used to protect adults and children against influenza (flu). It can only be used during a pandemic declared officially by the World Health Organization (WHO) or within the European Union (EU). A pandemic occurs when a strain of flu can spread easily from person to person because people have no immunity (protection) against it. Incellipan contains small amounts of proteins from the influenza virus. The virus has been inactivated so that it does not cause any disease in people who receive the vaccine.